Search results
...Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a...
Morningstar· 2 days ago(Nasdaq:KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced positive results from the primary analysis of TuHURA's ...
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as...
Benzinga· 3 days agoThe data will be presented today, on June...
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024...
The Pendulum· 4 days agoTiumBio Co., Ltd. (Kosdaq: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for patients with rare and incurable diseases, announced ...
TuHURA reports breakthrough in cancer vaccine trial By Investing.com
Investing.com· 1 day agoTuHURA Biosciences, Inc., in collaboration with Kintara Therapeutics, Inc. (NASDAQ:KTRA), has...
Alkermes impresses in full-throttle narcolepsy race with Takeda
FierceBiotech· 12 hours agoAlkermes has shown more of the data that persuaded it to throw money at its narcolepsy program. The phase 1b readout suggests Alkermes’ ALKS 2680 can hold ...
...Oral Presentation of Clinical Data of A Randomized ControlledPhase 1b Study Evaluating IBI310...
KOIN News 6 Portland· 2 days ago(HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and...
Genelux price target cut to $25 by Benchmark following shares offering By Investing.com
Investing.com· 4 days agoBenchmark has adjusted its price target on shares of Genelux Corp. (NASDAQ:GNLX), lowering it to $25...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 7 days agoImmunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously ...
Merck & Co. sees clear vision to new ophthalmology assets with $3B EyeBio buy
FierceBiotech· 7 days agoRestoret has already been tested in a phase 1b/2a trial called AMARONE in DME and neovascular age-related macular degeneration. Privately ...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 12 hours agoCARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO PR Newswire SHANGHAI, June 4, 2024 SHANGHAI, June 4, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative